Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Proficient Rx LP | 71205-941 | ORAL | 325 mg in 1 1 | 4/1/2022 | |
| Actavis Pharma, Inc. | 0591-0583 | ORAL | 225 mg in 1 1 | 2/28/2019 | |
| Vitruvias Therapeutics | 69680-132 | ORAL | 425 mg in 1 1 | 6/27/2019 | |
| Physicians Total Care, Inc. | 54868-4770 | ORAL | 150 mg in 1 1 | 12/6/2013 | |
| TWi Pharmaceuticals, Inc. | 24979-086 | ORAL | 325 mg in 1 1 | 6/20/2020 | |
| Zydus Pharmaceuticals (USA) Inc. | 68382-522 | ORAL | 225 mg in 1 1 | 3/23/2024 | |
| A-S Medication Solutions | 50090-4227 | ORAL | 225 mg in 1 1 | 1/1/2015 | |
| Actavis Pharma, Inc. | 0591-2287 | ORAL | 425 mg in 1 1 | 5/1/2019 | |
| Aurobindo Pharma Limited | 59651-256 | ORAL | 150 mg in 1 1 | 7/21/2023 | |
| Northstar Rx LLC | 16714-826 | ORAL | 325 mg in 1 1 | 10/7/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| MYLAN-PROPAFENONE | Mylan Pharmaceuticals ULC | 02457172 | Tablet - Oral | 150 MG | 10/31/2017 |
| RYTHMOL | BGP Pharma ULC | 00603708 | Tablet - Oral | 150 MG | 12/31/1988 |
| PROPAFENONE-300 | PRO DOC LIMITEE | 02243784 | Tablet - Oral | 300 MG | 5/26/2009 |
| APO-PROPAFENONE | 02243325 | Tablet - Oral | 300 MG | 2/22/2001 | |
| PROPAFENONE | sanis health inc | 02343053 | Tablet - Oral | 150 MG | 2/16/2010 |
| PROPAFENONE-150 | PRO DOC LIMITEE | 02243783 | Tablet - Oral | 150 MG | 3/7/2008 |
| MYLAN-PROPAFENONE | Mylan Pharmaceuticals ULC | 02457164 | Tablet - Oral | 300 MG | 10/31/2017 |
| PMS-PROPAFENONE | 02294559 | Tablet - Oral | 150 MG | 2/22/2008 | |
| MYL-PROPAFENONE | Mylan Pharmaceuticals ULC | 02245372 | Tablet - Oral | 150 MG | 3/8/2002 |
| PMS-PROPAFENONE | 02243728 | Tablet - Oral | 300 MG | 4/9/2001 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.